Claimed effect · Maridebart cafraglutide

Does Maridebart cafraglutide help with body weight?

B
Grade B — probable, not settled1 phase 2 RCT (465 in the obesity cohort, 52 wk) · effect size: large
Short answerProbable, not settled. Human data exist (1 phase 2 RCT (465 in the obesity cohort, 52 wk)) and mostly agree, showing a large effect — but too few, too small, or not yet peer-reviewed for a firm answer. Six dosing regimens of 140–420 mg every four or eight weeks. Intention-to-treat loss ranged from 12.3% to 16.2% against 2.5% on placebo. In the 127-person diabetes cohort, 8.4–12.3% against 1.7%.

What the studies show

Six dosing regimens of 140–420 mg every four or eight weeks. Intention-to-treat loss ranged from 12.3% to 16.2% against 2.5% on placebo. In the 127-person diabetes cohort, 8.4–12.3% against 1.7%.

“In the obesity cohort (465 participants; female sex, 63%; mean age, 47.9 years; mean body-mass index [BMI, the weight in kilograms divided by the square of the height in meters], 37.9), the mean percent change in body weight from baseline to week 52 on the basis of the treatment policy estimand (intention-to-treat approach) ranged from -12.3% (95% confidence interval [CI], -15.0 to -9.7) to -16.2% (95% CI, -18.9 to -13.5) with maridebart cafraglutide, as compared with -2.5% (95% CI, -4.2 to -0.7) with placebo.”

Verbatim, from the abstractJastreboff AM, et al. Once-monthly maridebart cafraglutide for the treatment of obesity — a phase 2 trial. N Engl J Med, 2025

Human trials exist and mostly agree, but there are too few of them, they are too small, or one big one is still reading out. Expect the grade to move.

  1. 1
    Jastreboff AM, et al. Once-monthly maridebart cafraglutide for the treatment of obesity — a phase 2 trial.N Engl J Med, 2025592 enrolled; obesity and obesity-diabetes cohorts; 52 weeks. NCT05669599.

In context

Maridebart cafraglutide, or MariTide, is an antibody that blocks the GIP receptor with two GLP-1-agonist peptides attached, injected once a month. In a 592-person phase 2 trial published in the New England Journal of Medicine in 2025, people with obesity lost 12–16% at 52 weeks against 2.5% on placebo. Gut side effects were common, less so with dose escalation. Phase 3 trials are running; it is not approved anywhere.

Maridebart cafraglutide is investigational (phase 3). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Maridebart cafraglutide proven to help with body weight?
Not yet settled. 1 phase 2 RCT (465 in the obesity cohort, 52 wk) — LYO grades it B, meaning probable but liable to change as trials read out.
What studies are behind the grade?
Six dosing regimens of 140–420 mg every four or eight weeks. Intention-to-treat loss ranged from 12.3% to 16.2% against 2.5% on placebo. In the 127-person diabetes cohort, 8.4–12.3% against 1.7%.
Is Maridebart cafraglutide approved for this?
No. Maridebart cafraglutide is investigational (phase 3); it is not an approved medicine for any indication in the jurisdictions LYO covers.

Other outcomes for Maridebart cafraglutide

Written and maintained by LYO Research — how pages are written and checked. Reviewed 23 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →